Maintenance Olaparib New Standard in Pancreatic Cancer?
In a phase III trial, olaparib maintenance therapy significantly extended progression-free survival and duration of response in patients with BRCA-mutated metastatic pancreatic cancer who responded to platinum-based chemotherapy, compared with a placebo. Based on the findings, which were presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL, maintenance olaparib is likely to become a new treatment option for these patients.